(Updated - December 11, 2024 6:20 AM EST)

Leerink Partners analyst Thomas Smith downgraded Q32 Bio Inc. (NASDAQ: QTTB) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Q32 Bio Inc. (QTTB) PT Lowered to $20 at OppenheimerDecember 11, 2024 6:37 AM Q32 Bio: Oppenheimer slashes price target on mixed trial resultsDecember 11, 2024 4:43 AM Wells Fargo Downgrades Q32 Bio Inc. (QTTB) to Equal WeightDecember 11, 2024 4:25 AM Raymond James Downgrades Q32 Bio Inc. (QTTB) to OutperformDecember 11, 2024 2:52 AM After-hours movers: GM, Stitch Fix, Dave & Buster's, GME and moreDecember 10, 2024 4:50 PM Q32 Bio (QTTB) SIGNAL-AD trial did not achieve its primary endpoint, SIGNAL-AA demonstrated encouraging clinical activityDecember 10, 2024 4:11 PM Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development ProgramDecember 10, 2024 4:05 PM